Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2022-12-13 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2022-12-13 English
News release - English.pdf
Regulatory Filings
2022-12-08 English
News release - English.pdf
Regulatory Filings
2022-12-05 English
News release - English.pdf
Regulatory Filings
2022-11-29 English
Material change report - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing the release of interim Q3 2022 consolidated financial results for Green Rise Foods Inc. It includes key financial highlights such as record revenue and adjusted EBITDA for the quarter and nine-month periods ended September 30, 2022. The text mentions that the full results and management discussion and analysis are available on SEDAR and the company's website, indicating this document is a summary announcement rather than the full interim report itself. The document length is 4622 characters, which is relatively short and consistent with a summary earnings release rather than a comprehensive interim report. The content focuses on key financial results and operational highlights for the quarter, typical of an Earnings Release (ER). It is not a full interim report (IR) because it does not contain detailed financial statements or substantive financial data and analysis, only highlights and a summary. Therefore, the appropriate classification is Earnings Release (ER). Q3 2022
2022-11-04 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 Material Change Report' and details material changes for Voyageur Pharmaceuticals Ltd. It includes dates of material changes, summaries, and full descriptions of these changes, including news releases about a memorandum of understanding and the design of a carbon neutral pharmaceutical plant. The document is a regulatory filing under Canadian securities law (NI 51-102) used to disclose material changes to investors and the market. It is not an annual or quarterly report, audit report, earnings release, or any other financial report type. It is a specific regulatory disclosure about material changes, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories. The document length is substantial and contains detailed information about the material changes, not just an announcement of a report publication. Therefore, the best classification is Regulatory Filings (RNS).
2022-11-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.